The draft recommendations contain guidelines for when manufacturers are required to notify the FDA regarding modifications made to medical devices already on the market.
The document specifies when these changes are extensive enough to justify FDA review.
“Medical device technology evolves quickly, and not all changes made to marketed devices alter their safety profile or require our review, “ said Jeffrey Shuren, MD, director of the FDA‘s Center for Devices and Radiological Health.
Once finalized, the guidance will replace an earlier one issued in 1997.
The FDA also issued a separate draft guidance to address software changes made to devices.
More articles on medical devices:
FDA will not regulate fitness trackers, wellness apps
MIT researchers create programmable device to produce biologics on the spot
GlaxoSmithKline and Google’s Alphabet team up for new biotech firm
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.